Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	41.18
Cost of Revenue	11.9	12.71	14.65	16.84	22.04
Gross Profit	-11.9	-12.71	-14.65	-16.84	19.14
Selling, General & Admin	9.95	10.41	10.58	13.33	17.29
Operating Expenses	9.95	10.41	10.58	13.33	17.29
Operating Income	-21.85	-23.12	-25.23	-30.17	1.85
Interest Expense	-4.56	-8.28	-7.41	-6.33	-
Interest & Investment Income	1.27	1.44	0.56	0.02	0.16
Currency Exchange Gain (Loss)	-0	-0.04	-0.03	-0.03	-0.07
Other Non Operating Income (Expenses)	26.58	-	-	-	-
EBT Excluding Unusual Items	1.44	-30.01	-32.11	-36.51	1.94
Asset Writedown	-	-	-	-15.2	-
Pretax Income	1.44	-30.01	-32.11	-51.71	1.94
Income Tax Expense	-	-	-	-1.8	-
Net Income	1.44	-30.01	-32.11	-49.91	1.94
Net Income to Common	1.44	-30.01	-32.11	-49.91	1.94
Shares Outstanding (Basic)	8	7	5	5	5
Shares Outstanding (Diluted)	8	7	5	5	5
Shares Change (YoY)	16.41%	21.84%	-	4.41%	4.88%
EPS (Basic)	0.19	-4.61	-6.01	-9.35	0.38
EPS (Diluted)	0.19	-4.61	-6.01	-9.35	0.38
Free Cash Flow	-19.55	-14.78	-24.66	-24.6	-33.82
Free Cash Flow Per Share	-2.58	-2.27	-4.62	-4.61	-6.61
Gross Margin	-	-	-	-	46.48%
Operating Margin	-	-	-	-	4.49%
Profit Margin	-	-	-	-	4.71%
Free Cash Flow Margin	-	-	-	-	-82.14%
EBITDA	-21.84	-23.11	-	-30.15	1.86
EBITDA Margin	-	-	-	-	4.52%
D&A For EBITDA	0.01	0.01	-	0.02	0.02
EBIT	-21.85	-23.12	-25.23	-30.17	1.85
EBIT Margin	-	-	-	-	4.49%
Revenue as Reported	-	-	-	-	41.18

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q